Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an average 12% body weight loss in a Phase 3 trial. The study, involving overweight or obese adults, revealed significant weight reduction and improved cardiovascular markers.
from Times of India https://ift.tt/hC29sWL
https://ift.tt/vRu2ALN
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an average 12% body weight loss in a Phase 3 trial. The study, involving overweight or obese adults, revealed significant weight reduction and improved cardiovascular markers.
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an average 12% body weight loss in a Phase 3 trial. The study, involving overweight or obese adults, revealed significant weight reduction and improved cardiovascular markers.
August 11, 2025 at 10:11PM
No comments:
Post a Comment